Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 206-768-5 | CAS number: 373-61-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Comparable to guideline study
Data source
Reference
- Reference Type:
- publication
- Title:
- Inhalation toxicity Studies with Boron Trifluoride
- Author:
- Rusch GM et al.
- Year:
- 1 986
- Bibliographic source:
- Toxicol. and Appl. Pharmacol., 83, 67-78
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- Deviations:
- not specified
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- 13319-75-0
- EC Number:
- 603-716-7
- Cas Number:
- 13319-75-0
- IUPAC Name:
- 13319-75-0
- Details on test material:
- Boron trifluoride dihydrate
- Source: Allied Corporation
- Batch number: no data
- Purity: The substance was tested in a dihydrate form which contained 63.87% of BF3.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Labs (Portage, Mich.)
- Age at study initiation: approximately 7 weeks old
- Weight at study initiation: no data
- Fasting period before study: no
- Housing: individually in suspended stainless-steel mesh cages
- Diet (e.g. ad libitum): ad libitum Purina Rat Chow 5001
- Water (e.g. ad libitum): ad libitum
- Acclimation period: for a minimum of 2 weeks
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure:
- whole body
- Vehicle:
- other: unchanged (no vehicle); (areosols of BF3 dihydrate)
- Details on inhalation exposure:
- Exposure Chamber Designs and Operation
Subchronic exposures were conducted in 1000-liter stainless-steel and glass exposure chambers, operated under negative pressure, with filtered, conditioned air.
The total air flow rate was approximately 350 liters/min, providing a t99 equilibration time of 13 min. These exposures were conducted for 6 hr/day, 5 days/week for 13 weeks.
Chamber air temperature and relative humidity were monitored at least twice daily with a YSI Model 47 Scanning Tele-Thermometer (Yellow Springs Instrument, Yellow Springs, Ohio) and an Airguide Model 605 humidity indicator (Airguide Instrument, Chicago, Ill.), respectively.
All animals were left in the chambers for a period of at least 30 min immediately following the exposure to allow for equilibration of the chamber atmosphere with clean air.
Test Atmosphere Generation Procedures
Test atmospheres in the subchronic study were generated with a DeVilbiss No. 40 Glass nebulizer (The DeVilbiss Company, Somerset, Pa.) and Sage Model 355 syringe pump (Sage Instruments, Cambridge, Mass.). The nebulizer was operated with compressed, breathing-grade air under conditions that rapidly aerosolized the liquid BF3 2H20. The rate of delivery, and thus the quantity of aerosol produced, was controlled by regulating the feed rate on the syringe pump.
Analysis of Chamber Concentrations
Nominal aerosol concentrations were determined daily by measuring the amount of test material consumed during the exposure and dividing this by the total airflow through the chamber. At hourly intervals, actual air concentration measurements were made by trapping aerosol samples on cellulose nitrate membrane filters, using a flow-Gmiting orifice (Millipore XX50000014) with a pump (Gast DOA-122) and dry test meter (Singer DTM-115-3) for volume measurement.
The aerosol was then dissolved in distilled water and analyzed for BF3 content by an ion-selective electrode technique (Carlson and Paul, 1968; Gulens and Lesson, 1980). Sample volumes were varied to permit collection of roughly equal quantities of BF3.
Particle size measurements were made with an Anderson I ACFM particle sizing sampler (Anderson 2000, Inc., Atlanta, Ga.). Measurements were performed twice each week during the subchronic exposures. The material collected on each stage was determined gravimetrically. - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 6 h/day, 5 d/week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 2, 6 and 17 mg/m3
Basis:
analytical conc.
- No. of animals per sex per dose:
- 20 males and 20 females
- Control animals:
- yes
- Details on study design:
- Post-exposure period: 2 weeks (5 animals/sex/dose group)
Examinations
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS AND FREQUENCY:
- Clinical signs: observed twice daily.
- Mortality: daily noted
- Body weight: recorded twice prior to the first exposure and once a week thereafter.
- Food consumption: no
- Ophthalmoscopic examination: no
- Haematology (complete blood counts), Biochemistry (blood urea nitrogen (BUN), serum glutamic-pyruvic transaminase (SGPT), alkaline phosphatase, glucose, albumin, total protein, globulin by difference, CA, P, Cl, Na and K) and Urinalysis (volume, osmolality, pH and creatinine : measured after one month of exposure in 5 animals/sex/dose, during the final week of the exposure period (15 animals/sex/dose) and at two weeks past the final exposure (retained group of five animals/sexe/dose).
In addition, determination of urinary ionic and total fluoride and serum total fluoride amounts was made at 1 and also 2 months of exposure (for urinary ionic and total fluoride only), during the final week of the exposure period and two weeks following the final exposure with the same animals selected for serum chemistry determinations.
ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
- Weighted organs: brain, heart, kidneys, liver, lungs (with trachea), ovaries, spleen and testes
- Macroscopic and microscopic examinations: Tissues from 40 major organs of high-exposure and control groups were examined. In addition, nasal turbinates, kidneys, lungs and liver were examinated from all other animals of the study. - Statistics:
- The results of measurements of all quantitative continuous variables such as body weight, hematology, and clinical chemistry data were intercompared, exposure groups to controls, by the use of the following tests: Bartlett's homogeneity of variance, analysis of variance, and Duncan's procedure. The latter was used if F for analysis of variance was significantly high to delineate which groups differed from the controls. If Bartlett's test indicated heterogenous variance, the F max test was used for each group versus the control. If these individual Fmax tests were not significant or N1 = N2 Student's t test was used; if significant, the means were compared by the Cochran t test or the Wilcoxon rank sum test.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS:
There was an increased incidence of dried material around the mouth and nose, rales and excessive lacrimation, primarily in the high-exposure group.
MORTALITY: One rat died in the high-exposure group. This death was attributed to the test substance. Two accidental deaths occurred.
BODY WEIGHT: No differences were observed between treated and control groups.
HAEMATOLOGY: No differences were observed between treated and control groups.
BLOOD CHEMISTRY: An exposure-related depression of total protein concentrations (up to 16%) accompanied by an exposure-related depression of globulin concentrations (up to 38%). One male from the high-exposure group had an elevated blood urea nitrogen. Serum fluoride concentration were markedly increased in all exposure groups (dose-related increase). A recovery was noted after the end of exposure.
URINALYSIS: An exposure-related depression in calcium amounts and an exposure-related increase in urinary fluoride were noted. The decrease in calcium values was found to be reversible at the end of exposure.
NECROPSY:
- Organ weight: No differences were observed between treated and control groups.
- Macroscopic findings: No specific changes were observed in treated groups when compared to control group.
- Microscopic findings: In the high-exposed dead male, necrosis of the renal tubular epithelium was seen. Another high-exposed rat also exhibited such a necrosis (this is the rat which had an elevated blood urea nitrogen).
Effect levels
open allclose all
- Dose descriptor:
- NOAEC
- Effect level:
- 6 mg/m³ air
- Sex:
- male/female
- Basis for effect level:
- other: kidney effects
- Dose descriptor:
- LOAEC
- Effect level:
- 17 mg/m³ air
- Sex:
- male/female
- Basis for effect level:
- other: Tubular necrosis in 2 male rats
- Dose descriptor:
- LOEC
- Effect level:
- 2 mg/m³ air
- Sex:
- male/female
- Basis for effect level:
- other: Increase of fluorine in urine and in blood samples
- Dose descriptor:
- LOEC
- Effect level:
- 6 mg/m³ air
- Sex:
- male/female
- Basis for effect level:
- other: Minimal findings of respiratory irritation
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
MEAN URINARY CALCIUM CONCENTRATIONS (mg/dl) | ||||||||
Exposure (mg/m3) | Males | Females | ||||||
Week 5 | Week 9 | Week 13 | Week 15 | Week 5 | Week 9 | Week 13 | Week 15 | |
0 | 7.70 a | 12.22 | 15.12 | 25.00 | 10.34 | 18.44 | 14.17 | 40.0 |
2.49 | 5.31 | 11.29 | 8.99 | 4.02 | 5.71 | 7.57 | 12.7 | |
3 | 5 | 20 | 5 | 5 | 5 | 20 | 3 | |
2 | 8.67 | 8.36 | 11.45 | 25.50 | 7.24 | 12.42 | 9.63 | 31.8 |
4.46 | 3.17 | 8.90 | 6.36 | 2.15 | 4.99 | 5.19 | 14.0 | |
4 | 5 | 20 | 5 | 5 | 5 | 20 | 5 | |
6 | 11.18 | 5.82* | 8.01* | 19.76 | 4.22** | 6.22** | 6.63** | 29.5 |
5.99 | 1.58 | 3.68 | 7.89 | 1.30 | 2.52 | 4.47 | 18.8 | |
5 | 5 | 20 | 5 | 5 | 5 | 19 | 4 | |
17 | 3.38 | 3.72** | 5.95** | 19.26 | 6.75 | 6.78** | 11.67 | 51.9 |
2.06 | 1.10 | 4.70 | 12.15 | 1.98 | 3.62 | 7.36 | 21.7 | |
5 | 5 | 19 | 5 | 4 | 5 | 20 | 5 | |
a Mean, standard deviation, number of animals evaluated. * Significantly different from control p< 0.05. ** Significantly different from control p< 0.01. |
URINARY FLUORIDE AND TOTAL FLUORINE AMOUNTS | ||||||||
Exposure (mg/m3) | Males | Females | ||||||
Week 5 | Week 9 | Week 13 | Week 15 | Week 5 | Week 9 | Week 13 | Week 15 | |
Urinary ionic fluoride amounts (µg) | ||||||||
0 | 14 a | 7 | 11 | 5 | 11 | 6 | ll | 7 |
2 | 5 | 8 | 1 | 2 | 1 | 6 | 6 | |
3 | 5 | 20 | 5 | 5 | 4 | 20 | 5 | |
2 | 121 | 160** | 257** | 86* | 192** | 187** | 251** | 57** |
57 | 62 | 98 | 30 | 59 | 37 | 79 | 19 | |
4 | 5 | 20 | 5 | 5 | 5 | 20 | 5 | |
6 | 175* | 211** | 228** | 114** | 340** | 240** | 382** | 68** |
67 | 85 | 104 | 50 | 39 | 83 | 103 | 35 | |
5 | 5 | 20 | 5 | 5 | 5 | 20 | 5 | |
17 | 418** | 430** | 412** | 140** | 409** | 346** | 453** | 64** |
82 | 61 | 212 | 79 | 72 | 78 | 144 | 16 | |
5 | 5 | 19 | 5 | 4 | 5 | 20 | 5 | |
Total urinary fluorine amounts (µg) | ||||||||
0 | 21 | 17 | 59 | 7 | 10 | 6 | 12 | 8 |
3 | 11 | 56 | 2 | 4 | 1 | 6 | 6 | |
5 | 4 | 20 | 5 | 5 | 4 | 20 | 5 | |
2 | 166 | 192 | 392 | 111 | 323 | 338 | 360* | 64 |
60 | 36 | 155 | 40 | 169 | 80 | 153 | 22 | |
4 | 5 | 20 | 5 | 5 | 5 | 20 | 5 | |
6 | 506 | 465 | 506- | 213 | 805** | 595* | 811** | 119** |
188 | 115 | 252 | 80 | 314 | 264** | 248 | 70 | |
5 | 5 | 20 | 5 | 5 | 5 | 20 | 5 | |
17 | 2201** | 2546* | 2021** | 476** | 1766** | 1592** | 1694** | 184** |
574 | 2221 | 1418 | 258 | 435 | 438 | 796 | 47 | |
5 | 5 | 19 | 5 | 4 | 5 | 20 | 5 | |
a Mean, standard deviation, number of animals evaluated. *Significantly different from control p< 0.05. **Significantly different from control p< 0.01. |
Exposure (mg/m3) | Males | Females | ||||
Week5 | Week13 | Week15 | Week5 | Week13 | Week15 | |
Total serum protein (g/dl) | ||||||
0 | 6.24 a | 7.29 | 6.92 | 6.80 | 7.15 | 7.03 |
0.31 | 0.27 | 0.42 | 0.35 | 0.17 | 0.15 | |
5 | 15 | 5 | 5 | 15 | 4 | |
2 | 5.90 | 6.91 | 7.18 | 5.94** | 6.79** | 7.00 |
0.26 | 0.46 | 0.26 | 0.50 | 0.25 | 0.34 | |
5 | 15 | 5 | 5 | 15 | 5 | |
6 | 6.16 | 6.89 | 6.98 | 6.06 | 6.74** | 6.88 |
0.29 | 0.45 | 0.26 | 0.34 | 0.16 | 0.27 | |
5 | 15 | 5 | 5 | 15 | 5 | |
17 | 6.14 | 6.56** | 6.90 | 5.74** | 6.67** | 6.94 |
0.30 | 0.65 | 0.27 | 0.23 | 0.20 | 0.15 | |
5 | 15 | 5 | 5 | 15 | 5 | |
Globulin (g/dl) | ||||||
0 | 1.60 | 2.59 | 2.06 | 2.62 | 2.63 | 2.93 |
0.31 | 0.30 | 0.21 | 0.63 | 0.17 | 0.28 | |
5 | 15 | 5 | 5 | 15 | 4 | |
2 | 1.56 | 2.36 | 2.40 | 1.88 | 2.35** | 2.94 |
0.33 | 0.39 | 0.14 | 0.51 | 0.20 | 0.42 | |
5 | 15 | 5 | 5 | 15 | 5 | |
6 | 1.78 | 2.31 | 2.20 | 1.86 | 2.31** | 2.78 |
0.23 | 0.43 | 0.26 | 0.31 | 0.15 | 0.15 | |
5 | 15 | 5 | 5 | 15 | 5 | |
17 | 1.86 | 2.09** | 2.30 | 1.66* | 2.27** | 2.70 |
0.25 | 0.54 | 0.63 | 0.49 | 0.15 | 0.12 | |
5 | 14 | 5 | 5 | 15 | 5 | |
a Mean, standard deviation, number of animals evaluated. * Significantly different from control p< 0.05. ** Significantly different from control p< 0.01. |
TOTAL SERUM FLUORINE AND BONE FLUORIDE | ||||||
Exposure (mg/m3) | Males | Females | ||||
Week 5 | Week 13 | Week 15 | Week 5 | Week 13 | Week 15 | |
Serum total fluorine (µg/ml) | ||||||
0 | 0.21 a | 0.27 | 0.19 | 0.46 | 0.28 | 0.10 |
0.17 | 0.16 | 0.06 | 0.12 | 0.09 | 0.03 | |
5 | 15 | 5 | 5 | 15 | 4 | |
2 | 0.36 | 0.98 | 0.38 | 0.81 | 2.26 | 0.29 |
0.05 | 0.35 | 0.10 | 0.27 | 0.32 | 0.14 | |
5 | 15 | 5 | 5 | 15 | 5 | |
6 | 1.04 | 2.17 | 1.15* | 2.82* | 3.46* | 0.77 |
0.23 | 0.6 | 0.42 | 1.33 | 1.00 | 0.56 | |
5 | 15 | 5 | 5 | 15 | 5 | |
17 | 3.32* | 8.94* | 1.65* | 5.06* | 7.25* | 2.97* |
1.11 | 0.69 | 0.65 | 0.88 | 2.97 | 0.51 | |
5 | 14 | 5 | 5 | 15 | 5 | |
Bone fluoride (µg/g) | ||||||
0 | 167 | 145 | 157 | 155 | ||
16 | 27 | 56 | 27 | |||
8 | 5 | 14 | 4 | |||
2 | 758* | 905* | 1159* | 1178* | ||
180 | 161 | 262 | 179 | |||
12 | 5 | 15 | 4 | |||
6 | 1119* | 1430* | 1564* | 1709* | ||
165 | 204 | 197 | 63 | |||
15 | 5 | 15 | 5 | |||
17 | 1554* | 2109* | 2289* | 2763* | ||
183 | 536 | 422 | 364 | |||
14 | 5 | 15 | 5 | |||
a Mean, standard deviation, number of animals evaluated. * Significantly different from control p< 0.01. |
Applicant's summary and conclusion
- Conclusions:
- The No Observed Adverse Effect Level (NOAEL) is 6 mg/m3 and the LOAEL is 17 mg/m3 for effects on kidney. The increase of fluorine amounts in serum and in urine are not considered as adverse since no signs of toxicity was associated and since it was reversible or partially reversible (as the recovery period was only 2 week, a full reversibility was not observed for urinary fluorine); nevertheless they are related to treatment.
- Executive summary:
The potential toxicity of Boron Trifluoride (BF3) was evaluated following repeated inhalation administration for 13 weeks, according to OECD Guideline 413. The substance was tested in a dihydrate form which contained 63.87% of BF3. Aerosols of BF3 dihydrate were administered daily by inhalation to Fischer 344 rats (20 Males and 20 Females), 6 hrs/day, 5 days a week, at the dose-levels of 0, 2, 6, 17 mg/m3 during 90 days.
Body weights were recorded pre-test, weekly and at death or prior necropsy. Animals were observed daily for toxicity and pharmacological effects, and twice daily for morbidity and mortality.
Whole blood, serum and plasma, and urine were sampled after one month of exposure in 5 animals/sex/dose, during the final week of the exposure period (15 animals/sex/dose) and in the retained animals (5/sex/dose) at the end of the post-exposure period. In addition, fluoride was measured in urine and in blood after 1 and 2 months of exposure and 2 weeks after the final exposure. All animals were examined for gross pathology, and organs were weighted and submitted to histopathology. Tissues from 40 major organs of high-exposure and control groups were examined. In addition, nasal turbinates, kidneys, lungs and liver were examinated from all other animals of the study.
At 17 mg/m3, one death was attributed to the test substance.
No differences were observed between treated and control groups for body weight and haematology. Urine analysis and blood chemistry were affected by treatment.
Clinical signs of respiratory irritation were seen, but without abnormal histological findings.
An exposure - related depression of total protein concentrations accompanied by an exposure-related depression of globulin concentrations was observed.
In urines, an exposure-related depression in calcium amounts and an exposure-related increase in urinary fluoride were noted. The decrease in calcium values was found to be reversible at the end of exposure, contrary to the decrease of urinary fluoride which was partially reversible.
Serum fluoride concentration were markedly increased in all exposure groups (dose-related increase). A recovery was noted after the end of exposure.
At necropsy, no differences for organ weight and macroscopic appearance were observed between treated and control groups. At microscopy examination, necrosis of the renal tubular epithelium was seen in the highest dose group and was the apparent cause of a death in one of the animals.
Consequently, under the experimental conditions, the No Observed Adverse Effect Level (NOAEL) is 6 mg/m3 and the LOAEL is 17 mg/m3 for effects on kidney. The increase of fluorine amounts in serum and in urine are not considered as adverse since no signs of toxicity was associated and since it was reversible or partially reversible (as the recovery period was only 2 week, a full reversibility was not observed for urinary fluorine); nevertheless they are related to treatment.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)